Palboxen (Palbociclib) Capsules

Indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer:

• 🔹 Initial therapy: In combination with an aromatase inhibitor (e.g., Letrozole) in postmenopausal women.
• 🔹 Subsequent therapy: In combination with Fulvestrant in women with disease progression following endocrine therapy.

Packaging: 125 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (28-day cycle):

• Dose: One capsule (125 mg) taken orally once daily.
• Schedule: Take for 21 consecutive days, followed by a 7-day break (no treatment).
• With Food: Must be taken with food to ensure consistent absorption.
• Avoid: Do not consume grapefruit or grapefruit juice during treatment.

• Hypersensitivity to Palbociclib.
• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Severe hepatic or renal impairment (dose adjustment may be required).

The most common adverse reaction is hematologic toxicity:

• 🩸 Neutropenia: Low white blood cell count is very common. Regular Complete Blood Counts (CBC) are mandatory before starting each cycle.
• 🌀 General: Fatigue, nausea, anemia, alopecia (hair thinning).
• 🤒 Infections: Increased risk of upper respiratory tract infections.